Read Today’s Newspaper
☰ Mobile Logo

Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA

22:02 June 15, 2020 |
Share Story

Hikma Pharmaceuticals PLC. (Hikma) and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) announced today that they have entered into an exclusive licensing and distribution agreement for ILUMYA, an innovative biologic product, for the Middle East and North Africa (MENA) region.

ILUMYA (tildrakizumab) is a USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Under the agreement, Hikma, the multinational pharmaceutical company, will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma, the world's fourth largest specialty generic pharmaceutical company, will be responsible for product supply. The agreement’s term is 15 years from first sale with a two-year automatic renewal post the expiration of the agreement.

In comment, Mazen Darwazah, Hikma’s executive vice chairman and president of MENA said, “We are excited to partner with Sun Pharma and bring ILUMYA to our patients in MENA.ILUMYA™ is the first innovative monoclonal antibody product we add to our portfolio.”

.col-lg-12.second .opinion-widget{border-top:1px solid #D0D0D0;} #widget_1623 .opinions-title {font-size:32px;}

{{articles_filter_1623_widget?.title}}

{{ articles_filter_1623[0]?.section_name }}

{{ articles_filter_1623[0]?.title }}
Opinion Author
{{ articles_filter_1623[1]?.author_name }}

{{ articles_filter_1623[1]?.title }}
.epaper-separator{ height: 1px; width: 100%; background-color: #D0D0D0; margin: 15px 0; }

Today’s Paper

Today's Paper
.related-articles .layout-ratio{padding-bottom:55%;}
Related Articles
.alert-success { color :#A3656F ; } .alert-danger { color : red ; } .footer { font-family:Myriad Pro,Arial; }
The Jordan Times Logo

The Jordan Times is an independent English-language daily published by the Jordan Press Foundation since October 26, 1975. The Jordan Press Foundation is a shareholding company listed on the Amman Stock Exchange.

Join Our Newsletters

Sign up by email to receive news.

Camera Icon Read Today’s Newspaper

Copyright © 2025 The Jordan Times. All Rights Reserved.

document.addEventListener('DOMContentLoaded', function () { function validateEmail(email) { return /^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(email); } function showModal(message,type) { const messageContainer = document.getElementById("messageContainerFooter"); messageContainer.textContent = message; messageContainer.className = `alert alert-${type} mt-3`; // Bootstrap alert styling messageContainer.classList.remove("d-none"); // Hide message after 5 seconds setTimeout(() => { messageContainer.classList.add("d-none"); }, 5000); } document.getElementById("emailFormFooter").addEventListener("submit", function(event) { event.preventDefault(); const emailInput = document.getElementById("emailFooter"); const email = emailInput.value.trim(); if (!validateEmail(email)) { showModal('Invalid email format','danger'); return; } const url = `/subscribeNewsletter?email=${encodeURIComponent(email)}`; fetch(url, { method: "GET", headers: { "Accept": "application/json" } }) .then(response => { if (!response.ok) { showModal("Error submitting email. Try again.",'danger'); } return response.json(); }) .then(data => { showModal(data.message,'success'); }) .catch(error => { showModal("Error submitting email. Try again.",'danger'); }); }); });